IL13 and asthma: Given the finding that phosphorylated STAT6 is the primary target for degradation upon PARP-1 inhibition, this represents a unique opportunity to target the transcription factor for degradation during asthma where the IL-4/IL-13/STAT6 pathway is upregulated especially in uncontrolled/severe disease [49].